Pharmacologic treatments for covid-19 patients

Regdanvimab (CT-P59) vs Placebo


Outpatients

Forest plots
(last update: 2022-11-22)

Summary of findings
(last update: 2022-11-24)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=351

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT04602000; EudraCT 2020-003369-20
Kim JY, Open Forum Infect Dis, 2022
Full text
Commentary
Commentary
Mixed

Regdanvimab

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated by 58 centers in Hungary, Ireland, Italy, Macedonia, Mexico, Moldova, Peru, Poland, Republic of Korea, Romania, Serbia, Spain, Ukraine, and the USA. N=1315
Some concerns
Details

Full description

NCT04602000, EudraCT: 2020-003369-20
Streinu-Cercel A, Open Forum Infect Dis, 2022
Full text
Commentary
Commentary
Mixed

Regdanvimab 80mg/kg

Placebo

RCT Outpatients with suspected or confirmed COVID-19 (mild-moderate) treated by 23 centers in South Korea, Romania, Spain and the USA. N=327
Some concerns
Details

Full description